Kim et al. (2019) corroborated these findings in the ADLPAPT mouse model of AD by showing that treating ADLPAPT mice from 2 months of age with WT FMT until 6 months of age resulted in a reduction in Aβ, tau phosphorylation, Iba1 + microglia, GFAP + astrocytes, Ly6Chigh monocytes, and better performance in contextual fear conditioning and Y maze [106]. Here, MAPT is linked to Alzheimer disease.